Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The company's product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TBPH
CUSIPN/A
Phone650-808-6000
Debt
Debt-to-Equity Ratio3.53
Current Ratio4.25
Quick Ratio4.08
Price-To-Earnings
Trailing P/E Ratio-4.39
Forward P/E Ratio-4.99
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.39 million
Price / Sales85.29
Cash FlowN/A
Price / CashN/A
Book Value$2.13 per share
Price / Book11.23
Profitability
EPS (Most Recent Fiscal Year)($5.45)
Net Income$-285,400,000.00
Net Margins-1,383.47%
Return on Equity-188.96%
Return on Assets-58.47%
Miscellaneous
Employees340
Outstanding Shares54,850,000
Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions
What is Theravance Biopharma's stock symbol?
Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."
How were Theravance Biopharma's earnings last quarter?
Theravance Biopharma Inc (NASDAQ:TBPH) announced its quarterly earnings data on Tuesday, May, 8th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, beating the consensus estimate of ($1.26) by $0.04. The biopharmaceutical company earned $8.32 million during the quarter, compared to analyst estimates of $5.74 million. Theravance Biopharma had a negative return on equity of 188.96% and a negative net margin of 1,383.47%. View Theravance Biopharma's Earnings History.
What price target have analysts set for TBPH?
6 Wall Street analysts have issued 12 month price objectives for Theravance Biopharma's shares. Their predictions range from $22.00 to $55.00. On average, they expect Theravance Biopharma's share price to reach $39.6667 in the next year. View Analyst Ratings for Theravance Biopharma.
What are Wall Street analysts saying about Theravance Biopharma stock?
Here are some recent quotes from research analysts about Theravance Biopharma stock:
- 1. Needham & Company LLC analysts commented, "Theravance provided a quarterly corporate update yesterday. Mgmt guided for TD-9855 data in Neurogenic Orthostatic Hypotension (NOH) in Jul 2018 (was 2Q18). Impact on symptoms (dizziness) through 4wks will be key. There are limitations to the trial, however, including a small number of patients and no placebo arm. Nevertheless, mgmt is optimistic for Phase 3 initiation by YE18. FDA reportedly requiring a large safety trial for velusetrag, prompting Theravance to stop development in the U.S. Collaborator Alfasigma consequently exercised its option for WW rights and will pursue development in EU. TD-1473 trial initiations in Disease are still on track for 2H18. Reiterate BUY, but reducing price target to $40 (was $45) to reflect decision not to develop velusetrag in U.S." (5/9/2018)
- 2. According to Zacks Investment Research, "Theravance has a single marketed product in its portfolio called Vibativ. Moreover, its pipeline programs are targeting highly competitive therapeutic areas. Also, any agreement termination might be a huge setback for the company as in the past. Shares of the company have underperformed the industry in a year’s time. However, we are upbeat about Theravance’s efforts to expand Vibativ’s label, which if approved for additional indications, would be commercially significant. Moreover, the company’s regulatory filing for revefenacin for treating chronic obstructive pulmonary disease was accepted by the FDA in January 2018 with a response expected by this year-end. Estimates have been going down lately ahead of the company’s Q1 earnings release. The company has negative record of earnings surprises in recent quarters." (5/1/2018)
- 3. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) An sNDA was filed for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD. TBPH is entitled to receive an 85% economic interest in the royalties paid by GSK (Not Covered) on worldwide net sales; 2) Trelegy Ellipta was granted marketing authorization in Europe for the treatment of COPD; 3) in November, TBPH and MYL (Neutral) announced the submission of an NDA for revefenacin (TD-4208) in adults with COPD; 4) at the 2017 Annual CHEST Meeting, TBPH and MYL announced the presentation of additional positive efficacy data from the three- month, pivotal Phase 3 studies of revefenacin (TD-4208); 5) progression of inhaled JAK inhibitor into first-in-human studies in late-2018/early-2019; 6) TBPH expects to provide an update in 1H18 regarding its dialogue with U.S. and EU regulators on Phase 3 requirements for the velusetrag/TD-5108 program in gastroparesis; 7) cash and equivalents totaled ~$390MM at 12/31/17. This excludes the $100MM upfront payment received in February 2018, from the announced collaboration with Janssen (Not Covered)." (2/27/2018)
Who are some of Theravance Biopharma's key competitors?
Some companies that are related to Theravance Biopharma include United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN) and Ironwood Pharmaceuticals (IRWD).
Who are Theravance Biopharma's key executives?
Theravance Biopharma's management team includes the folowing people:
- Mr. Rick E. Winningham, Chairman & CEO (Age 58)
- Ms. Renée D. Galá, Sr. VP, CFO & Treasurer (Age 46)
- Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 58)
- Dr. Sharathchandra S. Hegde, Sr. VP of Research (Age 54)
- Dr. Phillip D. Worboys, Sr. VP of Translational Science (Age 48)
Has Theravance Biopharma been receiving favorable news coverage?
News stories about TBPH stock have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Theravance Biopharma earned a news sentiment score of 0.10 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 44.98 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Theravance Biopharma's major shareholders?
Theravance Biopharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Woodford Investment Management Ltd (19.89%), BlackRock Inc. (6.54%), Northern Trust Corp (0.94%), Schwab Charles Investment Management Inc. (0.38%), Senzar Asset Management LLC (0.34%) and Jane Street Group LLC (0.26%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Brett K Haumann, Burton G Malkiel, Frank Pasqualone, Henrietta Fore, Renee D Gala and Rick E Winningham. View Institutional Ownership Trends for Theravance Biopharma.
Which institutional investors are selling Theravance Biopharma stock?
TBPH stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Legal & General Group Plc, Teacher Retirement System of Texas, Old West Investment Management LLC and California Public Employees Retirement System. Company insiders that have sold Theravance Biopharma company stock in the last year include Bradford J Shafer and Renee D Gala. View Insider Buying and Selling for Theravance Biopharma.
Which institutional investors are buying Theravance Biopharma stock?
TBPH stock was bought by a variety of institutional investors in the last quarter, including Woodford Investment Management Ltd, Jane Street Group LLC, Millennium Management LLC, Hound Partners LLC, Senzar Asset Management LLC, Alps Advisors Inc., Schwab Charles Investment Management Inc. and Xact Kapitalforvaltning AB. Company insiders that have bought Theravance Biopharma stock in the last two years include Burton G Malkiel, Frank Pasqualone, Henrietta Fore and Rick E Winningham. View Insider Buying and Selling for Theravance Biopharma.
How do I buy shares of Theravance Biopharma?
Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Theravance Biopharma's stock price today?
One share of TBPH stock can currently be purchased for approximately $23.93.
How big of a company is Theravance Biopharma?
Theravance Biopharma has a market capitalization of $1.30 billion and generates $15.39 million in revenue each year. The biopharmaceutical company earns $-285,400,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Theravance Biopharma employs 340 workers across the globe.
How can I contact Theravance Biopharma?
Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]
MarketBeat Community Rating for Theravance Biopharma (TBPH)
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
